The prognostic power of the TERT promoter mutation highlights its potential use as an important biomarker to predict the aggressive clinical behavior in melanoma, glioma, medulloblastoma, bladder cancer, thyroid cancer, urogenital cancer, and laryngeal cancer [9–11]. The gene discussed is TERT; the disease is urinary bladder cancer.